Immunohistochemistry Posters & Papers

• Introduction
• IHC on Mouse
• Recommended Diluent
• Ab Incubation
• Protocols
• Validation
• IHC Controls
• IHC Detection Reagents
• Clinically Relevant Targets

Posters

• Jian Yu, Susan Kane, Daiqiang Li, Herbert Haack, Bradley Smith, Ting-Lei Gu, Massimo Loda, Xinmin Zhou, Michael J. Comb (2008). Mutation Specific Antibodies for the Detection of EGFR Mutations in Non-Small Cell Lung Cancer. AACR Molecular Diagnostic in Cancer Therapeutic Development.
• Cynthia Shapiro, Angela Lightbown, Kathleen Rogers, Jessica Simendinger, Michael Lewis and Katherine Crosby (2007). Phospho-Specific Rabbit Monoclonal Antibodies Validated for Immunohistochemistry. National Society for Histotechnology.
• Jeremy Fisher, Kathleen Rogers, Katherine Crosby, Andrew Romano, Bradley L. Smith and Reginaldo Prioli (2007). The Detection of Phosphoproteins by Bio-Plex^® Assays in Cell, Xenograft and Human Tumor Lysate. Cambridge Healthtech Institute Protein Kinase Targets, Drug Discovery and Design.
• Kathleen Rogers, Katherine Crosby, Jeremy Fisher, Michael Lewis, Bradley L. Smith and Reginaldo Prioli (2007). Comparison of Bio-Plex^® Assays to Immunohistochemistry (IHC) for Measuring Phosphorylated Proteins in an In Vitro and In Vivo Model of Lung Cancer. Annual AACR.
• Qingfu Zeng, Katie Crosby, Ailan Guo, Bradley L. Smith and Roberto Polakiewicz (2006). Immunohistochemical Analysis of Potential Cell Signaling Biomarkers for Mutant Epidermal Growth Factor Receptor. USCAP.
• Cynthia Shapiro, Katherine Crosby, Michael Lewis and Bradley L. Smith (2006). Optimization and Validation of Activation-State Specific Antibodies for the Immunohistochemical Analysis of Fresh Frozen Tissues and Cells. National Society for Histotechnology.
• Katherine Crosby, Cynthia Shapiro, Michael Lewis, Angela Lightbown, Qingfu Zeng and Bradley L. Smith (2006). Comparison of Immunohistochemical Staining of Signaling Markers in Frozen and Paraffin-Embedded Tissues. Annual AACR.
• Angela Lightbown, Katherine Crosby, Qingfu Zeng, Michael Lewis and Bradley L. Smith (2005). Evaluation of PTEN: Immunohistochemical Analysis of Tissues and Cells. AACR Molecular Targets and Cancer Therapeutics.
• Katherine Crosby, Michael Lewis, Magdalene Laszczak, Qingfu Zeng, Angela Lightbown and Bradley L. Smith (2005). Comparison of Immunohistochemical and Western Blot Analyses of Paraffin-embedded Cells and Xenografts for Profiling Cellular Signaling. Annual AACR.

Papers

• Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK (2010) An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 70(6), 2485–94.
• Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, Maira SM, Ji H, Castrillon DH, Kim CF, García-Echeverría C, Bardeesy N, Sharpless NE, Hayes ND, Kim WY, Engelman JA, Wong KK (2010) Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17(6), 547–59.
• Ghosh R, Graham H, Rivas P, Tan XJ, Crosby K, Bhaskaran S, Schoolfield J, Banu J, Fernandes G, Yeh IT, Kumar AP (2010) Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management. Anticancer Res. 30(3), 857–65.
• Victoria Rimkunas, Katherine Crosby, Matt Silver, Krystyna Hincman, Meghan Kelly, Daiqiang Li, Xinmin Zhou and Herbert Haack (2010). Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific and sensitive immunohistochemistry-based assay and FISH analysis. American Society of Clinical Oncology (ASCO).
• Hudon V, Sabourin S, Dydensborg AB, Kottis V, Ghazi A, Paquet M, Crosby K, Pomerleau V, Uetani N, Pause A (2010) Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin. J. Med. Genet. 47(3), 182–9.
• Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15(2), 148–59.
• Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14(12), 1351–6.
• Rong L, Livingstone M, Sukarieh R, Petroulakis E, Gingras AC, Crosby K, Smith B, Polakiewicz RD, Pelletier J, Ferraiuolo MA, Sonenberg N (2008) Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA 14(7), 1318–27.
• Ghosh R, Garcia GE, Crosby K, Inoue H, Thompson IM, Troyer DA, Kumar AP (2007) Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia 9(11), 893–9.
• Kumar AP, Bhaskaran S, Ganapathy M, Crosby K, Davis MD, Kochunov P, Schoolfield J, Yeh IT, Troyer DA, Ghosh R (2007) Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin. Cancer Res. 13(9), 2784–94.
• Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M, Said J, De Kernion J, Reiter RE, Sawyers CL (2004) Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin. Cancer Res. 10(24), 8351–6.
• Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ (2005) Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 23(5), 982–9.
• Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, Bacus SS (2004) The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br. J. Cancer 91(6), 1190–4.
• Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS (2003) Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63(11), 2742–6.